TREATMENT FAILURE, TREATMENT SWITCHING AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS- RESULTS FROM A REAL WORLD SURVEY IN THE US

Author(s)

Deodhar A1, Strand V2, Conaghan PG3, Alten R4, Sullivan E5, Blackburn S5, Tian H6, Gandhi K6, Williams S7, Park Y6, Jugl SM8
1Oregon Health & Science University, Portland, OR, USA, 2Stanford University, Stanford, CA, USA, 3University of Leeds, Leeds, UK, 4Schlosspark-Klinik , University Medicine Berlin, Berlin, Germany, 5Adelphi Real World, Bollington, UK, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 7Novartis Pharmaceuticals, East Hanover, NJ, USA, 8Novartis Pharma AG, Basel, Switzerland

Presentation Documents

OBJECTIVES: To describe the use and switching of biologics among ankylosing spondylitis (AS) patients, and the correlates of treatment failure. METHODS: US Rheumatologists and their AS patients completed surveys capturing reasons for switching biologics, including primary lack of efficacy (1°LE, initial non-response) and secondary lack of efficacy (2°LE, loss of response over time). Patients reported HRQoL (SF-36, EQ-5D), work productivity and activity impairment (WPAI). Current biologic was determined as ‘failed’ if, after ≥3 months, rheumatologist perceived disease severity had worsened, remained severe, was ‘unstable’ or ‘deteriorating’, or they were dissatisfied with disease control, and/or did not consider treatment a ‘success’. RESULTS:

Conference/Value in Health Info

2017-05, ISPOR 2017, Boston, MA, USA

Value in Health, Vol. 20, No. 5 (May 2017)

Code

PMS55

Topic

Economic Evaluation, Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Work & Home Productivity - Indirect Costs

Disease

Musculoskeletal Disorders, Systemic Disorders/Conditions

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×